Liposomes as nanomedical devices

被引:1711
作者
Bozzuto, Giuseppina [1 ,2 ]
Molinari, Agnese [2 ]
机构
[1] CNR, Che Methodol Inst, Rome, Italy
[2] Ist Super Sanita, Dept Technol & Hlth, I-00161 Rome, Italy
关键词
liposomes; nanomedicine; drug delivery; ultrastructure; TEMPERATURE-SENSITIVE LIPOSOMES; DRUG-DELIVERY SYSTEM; LARGE UNILAMELLAR VESICLES; ATOMIC-FORCE MICROSCOPY; HUMAN TUMOR XENOGRAFT; PHASE-II; CATIONIC LIPOSOMES; IN-VITRO; CHARGED LIPOSOMES; POLYETHYLENE-GLYCOL;
D O I
10.2147/IJN.S68861
中图分类号
TB3 [工程材料学];
学科分类号
082905 [生物质能源与材料];
摘要
Since their discovery in the 1960s, liposomes have been studied in depth, and they continue to constitute a field of intense research. Liposomes are valued for their biological and technological advantages, and are considered to be the most successful drug-carrier system known to date. Notable progress has been made, and several biomedical applications of liposomes are either in clinical trials, are about to be put on the market, or have already been approved for public use. In this review, we briefly analyze how the efficacy of liposomes depends on the nature of their components and their size, surface charge, and lipidic organization. Moreover, we discuss the influence of the physicochemical properties of liposomes on their interaction with cells, half-life, ability to enter tissues, and final fate in vivo. Finally, we describe some strategies developed to overcome limitations of the "first-generation" liposomes, and liposome-based drugs on the market and in clinical trials.
引用
收藏
页码:975 / 999
页数:25
相关论文
共 282 条
[1]
Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice [J].
Afrin, F ;
Rajesh, R ;
Anam, K ;
Gopinath, M ;
Pal, S ;
Ali, N .
INFECTION AND IMMUNITY, 2002, 70 (12) :6697-6706
[2]
Lipid-quanturn dot bilayer vesicles enhance tumor cell uptake and retention in vitro and in vivo [J].
Al-Jamal, Wafa T. ;
Al-Jamal, Khuloud T. ;
Tian, Bowen ;
Lacerda, Lara ;
Bornans, Paul H. ;
Frederik, Peter M. ;
Kostarelos, Kostas .
ACS NANO, 2008, 2 (03) :408-418
[3]
Liposomes: From a Clinically Established Drug Delivery System to a Nanoparticle Platform for Theranostic Nanomedicine [J].
Al-Jamal, Wafa' T. ;
Kostarelos, Kostas .
ACCOUNTS OF CHEMICAL RESEARCH, 2011, 44 (10) :1094-1104
[4]
Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials [J].
Alberts, DS ;
Muggia, FM ;
Carmichael, J ;
Winer, EP ;
Jahanzeb, M ;
Venook, AP ;
Skubitz, KM ;
Rivera, E ;
Sparano, JA ;
Dibella, NJ ;
Stewart, SJ ;
Kavanagh, JJ ;
Gabizon, AA .
SEMINARS IN ONCOLOGY, 2004, 31 (06) :53-90
[5]
Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression [J].
Aleku, Manuela ;
Schulz, Petra ;
Keil, Oliver ;
Santel, Ansgar ;
Schaeper, Ute ;
Dieckhoff, Britta ;
Janke, Oliver ;
Endruschat, Jens ;
Durieux, Birgit ;
Roeder, Nadine ;
Loeffler, Kathrin ;
Lange, Christian ;
Fechtner, Melanie ;
Moepert, Kristin ;
Fisch, Gerald ;
Dames, Sibylle ;
Arnold, Wolfgang ;
Jochims, Karin ;
Giese, Klaus ;
Wiedenmann, Bertram ;
Scholz, Arne ;
Kaufmann, Joerg .
CANCER RESEARCH, 2008, 68 (23) :9788-9798
[6]
ALLEN TM, 1992, CANCER RES, V52, P2431
[7]
Liposomes - Opportunities in drug delivery [J].
Allen, TM .
DRUGS, 1997, 54 (Suppl 4) :8-14
[8]
Allen TM, 1995, LIPOSOMES NEW SYSTEM, P125
[9]
LIPOSOMES AS IMMUNOLOGICAL ADJUVANTS [J].
ALLISON, AC ;
GREGORIADIS, G .
NATURE, 1974, 252 (5480) :252-252
[10]
Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®):: Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer [J].
Andreopoulou, E. ;
Gaiotti, D. ;
Kim, E. ;
Downey, A. ;
Mirchandani, D. ;
Hamilton, A. ;
Jacobs, Allan ;
Curtin, John ;
Muggia, F. .
ANNALS OF ONCOLOGY, 2007, 18 (04) :716-721